Cell death and IL-18 release were significantly reduced in unprimed and IFN-γ-primed hMDMs treated with CASP4 or both CASP4 and CASP5 siRNA prior to infection with T4SS+ Lp, compared to control siRNA-treated cells (Fig. 2D and E). This evidence concerns the gene CASP4 and infection.